Breaking News Instant updates and real-time market news.

NBIX

Neurocrine

$88.65

-11 (-11.04%)

15:12
11/14/18
11/14
15:12
11/14/18
15:12

Neurocrine slides as Ingrezza serious cases count updated in FDA system

Shares of Neurocrine Biosciences (NBIX) are sliding after the Food and Drug Administration's Adverse Events Reporting System was updated with new quarterly data, showing 77 death cases identified for the company's Ingrezza among 445 serious cases in 2018. SERIOUS CASES IDENTIFIED FOR INGREZZA: The FDA's FAERS website, which appears to have been updated recently with quarterly data through September 30, shows 77 death cases identified for Neurocrine Biosciences' Ingrezza among 445 serious cases in 2018, compared with 11 fatalities and 96 serious cases last year. The FDA website, however, carries a cautionary note that there is no certainty the events reported to its database are due to the product in question. FAERS data does not confirm causality. Commenting on the data, Neurocrine Biosciences' representative Navjot Rai said the company does not believe there is any association between the use of Ingrezza and the casualties reported on FAERS, Bloomberg reported. "We remain confident in our products and our pipeline, as well as Neurocrine's prospects for continued growth and value creation," Rai said. Ingrezza is a prescription medicine used to treat adults with tardive dyskinesia. PRICE ACTION: In afternoon trading, shares of Neurocrine Biosciences have plunged more than 11% to $88.45.

  • 14

    Nov

NBIX Neurocrine
$88.65

-11 (-11.04%)

11/13/18
LEER
11/13/18
INITIATION
Target $110
LEER
Market Perform
Neurocrine initiated with a Market Perform at Leerink
Leerink analyst Marc Goodman started Neurocrine with a Market Perform and $110 price target as he initiates Neuroscience space with a Positive View. The analyst believes the Neuroscience sector is experiencing a "renaissance" as multiple new agents and mechanisms are coming up the pipeline across major therapeutic areas, the number of clinical studies is growing nicely, and the FDA is friendly to innovation in this space, companies are getting smarter about speed-to-market strategies and selecting niche sub-populations to focus on for initial product approvals, payer pushback on usage is much lower than in other categories, and physicians are enthusiastic about new agents. Regarding Neurocrine, Goodman believes Ingrezza should be a significant product for TD/TS but consensus sales expectations are already high.
11/12/18
LEER
11/12/18
INITIATION
Target $110
LEER
Market Perform
Neurocrine initiated with a Market Perform at Leerink
Leerink Partners analyst Marc Goodman started Neurocrine Biosciences with a Market Perform rating and $110 price target.
10/05/18
PIPR
10/05/18
NO CHANGE
Target $115
PIPR
Overweight
Piper positive on Neurocrine potential in Tourette's after doctor survey
After conducting a survey of 25 psychiatrists who manage pediatric patients with Tourette syndrome, Piper Jaffray analyst David Amsellem has heightened confidence that Neurocrine Biosciences' Ingrezza will have a significant role in the treatment landscape. To the extent that there is a label expansion in Tourette's, the product is likely to be seen as a more attractive dopaminergic-based agent relative to atypical antipsychotics, Amsellem tells investors in a research note. The analyst continues to believe that the upside potential for Neurocrine shares associated with favorable results in Tourette's is "significantly larger than the downside risk associated with a clinical setback." He reiterates an Overweight rating on the shares with a $115 price target.
09/20/18
STFL
09/20/18
NO CHANGE
Target $142
STFL
Buy
Neurocrine odds of success in Tourette's raised to 75% at Stifel
Stifel analyst Paul Matteis said his additional research on approved Tourette's Syndrome therapies, treatment guidelines, and the details of the T-FORCE GOLD study make him bullish that Neurocrine's valbenazine should succeed in its "very well powered" Phase 3 trial. The analyst, who believes the stock currently prices in a 40%-50% probability of success, raised his own take on the odds of success for the valbenazine program to 75% from 60%. He keeps a Buy rating on Neurocrine shares and increased his price target on the stock to $142 from $137.

TODAY'S FREE FLY STORIES

NBY

NovaBay

$0.53

0.0089 (1.72%)

07:13
09/18/19
09/18
07:13
09/18/19
07:13
Initiation
NovaBay initiated  »

NovaBay initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 09

    Oct

LECO

Lincoln Electric

$89.48

0.38 (0.43%)

07:13
09/18/19
09/18
07:13
09/18/19
07:13
Downgrade
Lincoln Electric rating change  »

Lincoln Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCSC

Scansource

$30.64

-0.6 (-1.92%)

07:12
09/18/19
09/18
07:12
09/18/19
07:12
Conference/Events
Scansource management to meet with Northcoast »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

BYSI

BeyondSpring

$19.60

-0.21 (-1.06%)

07:12
09/18/19
09/18
07:12
09/18/19
07:12
Hot Stocks
BeyondSpring sees sufficient cash to submit NDAs in China for Plinabulin »

As of June 30, 2019, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

FDX

FedEx

$173.53

-0.14 (-0.08%)

07:11
09/18/19
09/18
07:11
09/18/19
07:11
Recommendations
FedEx analyst commentary  »

FedEx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 13

    Nov

  • 17

    Dec

BYSI

BeyondSpring

$19.60

-0.21 (-1.06%)

07:11
09/18/19
09/18
07:11
09/18/19
07:11
Earnings
BeyondSpring reports Q2 EPS (32c), one est. (27c) »

"During the second…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

SBAC

SBA Communications

$252.94

6.55 (2.66%)

07:10
09/18/19
09/18
07:10
09/18/19
07:10
Conference/Events
SBA Communications management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

ADBE

Adobe

$284.59

1.54 (0.54%)

07:09
09/18/19
09/18
07:09
09/18/19
07:09
Recommendations
Adobe analyst commentary  »

Adobe price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

WLTW

Willis Towers Watson

$198.60

3.52 (1.80%)

07:08
09/18/19
09/18
07:08
09/18/19
07:08
Hot Stocks
Willis Research Network partners with Mitiga Solutions on aviation initiative »

The Willis Research…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

PM

Philip Morris

$71.98

-0.54 (-0.74%)

, MO

Altria Group

$41.31

-0.1 (-0.24%)

07:08
09/18/19
09/18
07:08
09/18/19
07:08
Recommendations
Philip Morris, Altria Group analyst commentary  »

Philip Morris, Altria…

PM

Philip Morris

$71.98

-0.54 (-0.74%)

MO

Altria Group

$41.31

-0.1 (-0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROKU

Roku

$150.43

0.86 (0.57%)

07:08
09/18/19
09/18
07:08
09/18/19
07:08
Recommendations
Roku analyst commentary  »

Roku price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RUBI

Rubicon Project

$9.41

0.24 (2.62%)

07:07
09/18/19
09/18
07:07
09/18/19
07:07
Conference/Events
Rubicon Project management to meet with B. Riley FBR »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

  • 30

    Sep

GIS

General Mills

$55.03

0.48 (0.88%)

07:07
09/18/19
09/18
07:07
09/18/19
07:07
Earnings
General Mills backs FY20 adj. EPS growth guidance of 3%-5% »

Reaffirms FY20 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 24

    Sep

  • 01

    Oct

PLUG

Plug Power

$2.72

-0.04 (-1.45%)

07:07
09/18/19
09/18
07:07
09/18/19
07:07
Hot Stocks
Plug Power announces hydrogen supply agreement with United Hydrogen »

Plug Power and United…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

REXR

Rexford Industrial

$44.50

0.01 (0.02%)

07:07
09/18/19
09/18
07:07
09/18/19
07:07
Hot Stocks
Rexford Industrial acquires industrial park for $66.2M »

Rexford Industrial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKTS

Akoustis

$7.90

0.1 (1.28%)

07:06
09/18/19
09/18
07:06
09/18/19
07:06
Downgrade
Akoustis rating change  »

Akoustis downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 12

    Nov

BK

BNY Mellon

$46.35

-0.4 (-0.86%)

07:06
09/18/19
09/18
07:06
09/18/19
07:06
Hot Stocks
BNY Mellon announces strategic alliance with Bloomberg »

The Bank of New York…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

NEXT

NextDecade

$6.30

-0.1 (-1.56%)

, ENB

Enbridge

$35.27

0.1 (0.28%)

07:06
09/18/19
09/18
07:06
09/18/19
07:06
Hot Stocks
NextDecade, Enbridge announce MOU to develop pipelines in South Texas »

NextDecade (NEXT) and…

NEXT

NextDecade

$6.30

-0.1 (-1.56%)

ENB

Enbridge

$35.27

0.1 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCI

Navigant Consulting

$27.93

0.05 (0.18%)

07:05
09/18/19
09/18
07:05
09/18/19
07:05
Conference/Events
Navigant Consulting management to meet with Barrington »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 10

    Oct

PLUG

Plug Power

$2.72

-0.04 (-1.45%)

07:04
09/18/19
09/18
07:04
09/18/19
07:04
Hot Stocks
Plug Power announces five-year plan targeting $1B of revenue by 2024 »

Plug Power has rolled out…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

QUIK

QuickLogic

$0.38

0.0025 (0.66%)

07:04
09/18/19
09/18
07:04
09/18/19
07:04
Hot Stocks
QuickLogic, Airoha announce Bluetooth collaboration »

QuickLogic announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

GIS

General Mills

$55.03

0.48 (0.88%)

07:04
09/18/19
09/18
07:04
09/18/19
07:04
Earnings
General Mills reports Q1 adj. EPS 79c, consensus 77c »

Reports Q1 revenue $4B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 24

    Sep

  • 01

    Oct

OII

Oceaneering

$14.80

-0.79 (-5.07%)

, BHGE

Baker Hughes

$23.37

-0.43 (-1.81%)

07:04
09/18/19
09/18
07:04
09/18/19
07:04
Hot Stocks
Oceaneering awarded contracts to supply subsea umbilicals by Baker Hughes »

Oceaneering (OII) has…

OII

Oceaneering

$14.80

-0.79 (-5.07%)

BHGE

Baker Hughes

$23.37

-0.43 (-1.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPW

Medical Properties Trust

$19.04

0.22 (1.17%)

07:03
09/18/19
09/18
07:03
09/18/19
07:03
Conference/Events
Medical Properties Trust management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

SQ

Square

$59.61

0.35 (0.59%)

07:03
09/18/19
09/18
07:03
09/18/19
07:03
Upgrade
Square rating change  »

Square upgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 06

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.